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before inclusion diagnosed -histological conﬁrmed-, in any pro-
gression state and already treated or under treatment. All diag-
nosis methods used and health care utilization resources were
collected, expressed their cost as 2007 €. RESULTS: A total of
1404 patients (pts) have been evaluated (mean age: 70.2  8.6).
Nine percent of pts were diagnosed by screening PSA programs,
50% by either general practitioner or specialist and 42% by
urologist. Screening programs were performed signiﬁcantly more
frequent in younger pts (<45 años), with University degree, famil-
iar precedent and workers in assets. Three consecutive phases
on diagnosis process were identiﬁed: 1)First PSA origin,
2)Conﬁrmation/Differentiation and 3)Extension study. 1st step
included: opportunistic screening, physician recognition, com-
plete med tests and PSA; 2nd: Transrectal ultrasonografy, pros-
tate biopsy and Gleason; & 3rd: Computed tomography (CT)
magnetic resonance imaging (MRI), urography, isotopic bone
scan (IBS), abdominal sonography and PET. Any additional step/
test were added based on clinical criteria. Based on International
Guidelines: 77.6% of IBS were well done vs. 43.8% not recom-
mended; CT 64.8% vs 48.8% not. Final total cost, in case all
steps/procedures were done, was €2339.95  680.14, and for
each step: 1st €246.47  0.0€, 2nd €1650.17  587.27 and 3rd
€511.43  313.42. CONCLUSIONS: Prostate cancer diagnosis
methods in Spain are widely variable. Gold standards are not
followed strictly. Potential savings for Spanish NHS could be
gather if additional not recommended test were not done increas-
ing adherenc to gold standards.
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NEW OPPORTUNITIES FOR DRUG OUTCOMES RESEARCH IN
CANCER PATIENTS: VALIDATION OFTHE LINKAGE OFTHE
EINDHOVEN CANCER REGISTRY ANDTHE PHARMO RECORD
LINKAGE SYSTEM
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OBJECTIVES: To validate the linkage of the Eindhoven Cancer
Registry (ECR) and the PHARMO Record Linkage System
(PHARMO RLS). METHODS: The ECR records data on all
newly diagnosed cancer patients in the Southeastern Netherlands
whereas the PHARMO RLS includes data on e.g. in- and outpa-
tient drug use, hospital morbidity and clinical laboratory. The
overlapping catchment area of both registries includes approxi-
mately 1 million inhabitants. The linkage of the ECR and
PHARMO RLS was performed with the PHARMO Probabilistic
Record Linkage Engine. After pairing records from both regis-
tries on date of birth and gender, a linkage weight was calculated,
based on ﬁrst initial, ﬁrst letter last name and 4-digit zip code.
The suggested threshold weight was used to divide pairs in
correct and incorrect linked pairs, i.e. pairs that include infor-
mation from both registries that point to the same or to different
patients, respectively. The sensitivity and speciﬁcity of this
linkage process was validated using a random subset of linked
and non-linked patients which were compared with a ‘gold-
standard’ using detailed personal information from the original
data sources. RESULTS: Of N = 58,197 cancer patients from the
ECR living in the PHARMO catchment area, N = 47,012(81%)
were linked to a patient from the PHARMO RLS and regarded as
being the same patient. The validated subset consisted of 2887
true positive linked pairs and the linkage of this subset yielded a
speciﬁcity of 99.5% (95% CI: 99.4%–99.7%) and a sensitivity
of 98.3% (95% CI: 97.7%–98.7%). CONCLUSIONS: The
linkage of the ECR and the PHARMO RLS is highly sensitive
and speciﬁc. The new linked database includes of more than 80%
of the cancer patients detailed information on in- and outpatient
drug treatment, co-medication, co-morbidity and other clinical
and economical details and can be used as a new source for
outcomes research in cancer treatment and post-marketing sur-
veillance of drug-induced cancer.
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OBJECTIVES: Financial access to medical technologies in the
United States may be driven by many factors, including drug
costs, health insurance coverage, beneﬁt designs, and patients’
ability or willingness to pay for treatment. Studies evaluating
out-of-pocket costs for cancer treatment have been conducted;
however, no national models of ﬁnancial access currently exist.
METHODS: We developed a conceptual framework for an inter-
active model of ﬁnancial access to cancer therapy. To illustrate
the model’s operation, we applied it to treatment of
HER2+ breast cancer patients. The model traces the ﬂow of
patients along pathways of a decision tree. Beginning with the US
population, the model branches by sex, breast cancer or no
breast cancer, HER2+ or HER2- cancer, and insurance status.
Only patients in the HER2+ branch are followed forward
through the model. Patients are stratiﬁed by payor and beneﬁt
design, eligibility for patient assistance programs, and ability to
pay for treatment without spending more than a pre-speciﬁed
percentage of family income out-of-pocket. Data sources include
custom analyses of publicly available databases (to determine
incidence/prevalence and the annual income and expenditures of
breast cancer patients), clinical trial data on dosages, and
national survey data on the proportion of patients with different
beneﬁt designs. The user interface allows for unlimited variations
in key input parameters. RESULTS: Model outputs include a
series of graphs showing ﬁnancial access before and after adding
speciﬁc treatments, with and without support from patient assis-
tance programs. Results are presented by payor, age, and income.
Sensitivity analyses can be conducted to evaluate the robustness
of results. CONCLUSIONS: While it is difﬁcult to ascertain the
number of patients who are not receiving treatment because of
ﬁnancial barriers, it is possible to develop a model that appro-
priately considers the main drivers of ﬁnancial access to estimate
the impact of ﬁnancial barriers.
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DEALING WITH QUALITY OF LIFE MISSING DATA IN A
SINGLE ARM STUDY. COMPARISON OF MULTIPLE
IMPUTATION METHODS
Arnault A1, Ivanescu C2, van Engen A2, Peeters P1
1Quintiles Consulting, Levallois-Perret, France, 2Quintiles Consulting,
Hoofddorp,The Netherlands
OBJECTIVES: Assessment of Quality of Life (QoL), a Patient
Reported Outcome (PRO), has gained acceptance as a study
endpoint. An open-label, multicenter phase II, single arm oncol-
ogy study was conducted with a QoL endpoint aiming to assess
change of scores from baseline to 12-week or End of Study
(whichever occurred ﬁrst). This required the availability of the
baseline and at least one post-baseline assessment. Unfortunately,
missing data affects the validity of QoL assessment. A set of
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